<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04231409</url>
  </required_header>
  <id_info>
    <org_study_id>92285183</org_study_id>
    <nct_id>NCT04231409</nct_id>
  </id_info>
  <brief_title>Fast-Acting Subperception Study (FAST)</brief_title>
  <acronym>FAST</acronym>
  <official_title>Study to Demonstrate the Value of Fast-Acting Subperception (FAST) Using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain (COMBO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to Demonstrate the Value of Fast-Acting Subperception (FAST) using the Spectra
      WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Pain Responder Rate</measure>
    <time_frame>3 months post-randomization</time_frame>
    <description>Proportion of subjects with 50% or greater reduction from Baseline Visit in average overall pain intensity at 3 months post-randomization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>WaveWriter Settings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>WaveWriter Programming</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Settings</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Programming</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Boston Scientific Spectra WaveWriter SCS System</intervention_name>
    <description>The Spectra WaveWriter Spinal Cord Stimulator (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, Complex Regional Pain Syndrome (CRPS) Types I and II, intractable low back pain and leg pain.</description>
    <arm_group_label>Conventional Settings</arm_group_label>
    <arm_group_label>WaveWriter Settings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic pain of the trunk and/or limbs for at least 6 months with back pain greater or
             equal to leg pain.

          -  22 years of age or older at time of enrollment

          -  Able to independently read and complete all questionnaires and assessments provided in
             English

          -  Signed a valid, IRB-approved informed consent form (ICF) provided in English

        Key Exclusion Criteria:

          -  Any pain-related diagnosis or medical/psychological condition that, in the clinician's
             best judgment, might confound reporting of study outcomes

          -  Significant cognitive impairment that, in the opinion of the Investigator, would
             reasonably be expected to impair the study candidate's ability to participate in the
             study

          -  Breast-feeding or planning to get pregnant during the course of the study or not using
             adequate contraception

          -  Participating, or intends to participate, in another clinical trial that may influence
             the data that will be collected for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wallace</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Bloom Lyons</last_name>
    <phone>763-228-9040</phone>
    <email>natalie.bloomlyons@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Keesey</last_name>
    <phone>661-949-4175</phone>
    <email>diane.keesey@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boston Scientific</last_name>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

